Formulation of the Prefusion RSV F Protein with a Th1/Th2-balanced Adjuvant Provides Complete Protection Without Th2-skewed Immunity in RSV-experienced Young Mice

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2020 Aug 25

PMID 32829976

Citations 12

Authors

Jessica L Kosanovich

Katherine M Eichinger

Madeline A Lipp

Mark A Yondola

Timothy N Perkins

Kerry M Empey

Affiliations

Soon will be listed here.

Abstract

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections among infants with most infections occurring in the first year of life. Multiple RSV exposures are required for children to mount adult-like immune responses. Although adult RSV immunity is associated with less severe disease, the protection induced through natural infection is short-lived. Therefore, vaccination of RSV-experienced young children may accelerate immunity and provide long-term protection from RSV reinfection. However, the extent to which different Th-biased vaccine regimens influence pre-existing humoral and cellular immunity in RSV-experienced young children is unknown. To address this question, infant BALB/c mice were RSV-infected and subsequently immunized with the prefusion RSV F (PreF) antigen formulated with either a Th2-skewing (Alum) or Th1/Th2-balanced (Advax-SM) adjuvant. These studies show that both adjuvants boosted neutralizing antibody and protected from RSV reinfection, but Advax-SM adjuvant prevented the Th2-skewed immunity observed in RSV-experienced young mice immunized with PreF/Alum.

Citing Articles

Recombinant RSV G protein vaccine induces enhanced respiratory disease via IL-13 and mucin overproduction.

Kawahara E, Senpuku K, Kawaguchi Y, Yamamoto S, Yasuda K, Kuroda E NPJ Vaccines. 2024; 9(1):187.

PMID: 39394212 PMC: 11470036. DOI: 10.1038/s41541-024-00987-w.

Lung ILC2s are activated in BALB/c mice born to immunized mothers despite complete protection against respiratory syncytial virus.

Kosanovich J, Eichinger K, Lipp M, Gidwani S, Brahmbhatt D, Yondola M Front Immunol. 2024; 15:1374818.

PMID: 38827738 PMC: 11140082. DOI: 10.3389/fimmu.2024.1374818.

Engineered dityrosine-bonding of the RSV prefusion F protein imparts stability and potency advantages.

Gidwani S, Brahmbhatt D, Zomback A, Bassie M, Martinez J, Zhuang J Nat Commun. 2024; 15(1):2202.

PMID: 38485927 PMC: 10940300. DOI: 10.1038/s41467-024-46295-8.

Ally, adversary, or arbitrator? The context-dependent role of eosinophils in vaccination for respiratory viruses and subsequent breakthrough infections.

Chang L, Schotsaert M J Leukoc Biol. 2024; 116(2):224-243.

PMID: 38289826 PMC: 11288382. DOI: 10.1093/jleuko/qiae010.

Exacerbated lung inflammation following secondary RSV exposure is CD4+ T cell-dependent and is not mitigated in infant BALB/c mice born to PreF-vaccinated dams.

Kosanovich J, Eichinger K, Lipp M, Gidwani S, Brahmbhatt D, Yondola M Front Immunol. 2023; 14:1206026.

PMID: 37646035 PMC: 10461110. DOI: 10.3389/fimmu.2023.1206026.

References

Dakhama A, Park J, Taube C, Joetham A, Balhorn A, Miyahara N . The enhancement or prevention of airway hyperresponsiveness during reinfection with respiratory syncytial virus is critically dependent on the age at first infection and IL-13 production. J Immunol. 2005; 175(3):1876-83. DOI: 10.4049/jimmunol.175.3.1876. View

COHN L, Homer R, Niu N, Bottomly K . T helper 1 cells and interferon gamma regulate allergic airway inflammation and mucus production. J Exp Med. 1999; 190(9):1309-18. PMC: 2195688. DOI: 10.1084/jem.190.9.1309. View

Culley F, Pollott J, Openshaw P . Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J Exp Med. 2002; 196(10):1381-6. PMC: 2193991. DOI: 10.1084/jem.20020943. View

Graham B, Perkins M, Wright P, Karzon D . Primary respiratory syncytial virus infection in mice. J Med Virol. 1988; 26(2):153-62. DOI: 10.1002/jmv.1890260207. View

Miyahara N, Takeda K, Kodama T, Joetham A, Taube C, Park J . Contribution of antigen-primed CD8+ T cells to the development of airway hyperresponsiveness and inflammation is associated with IL-13. J Immunol. 2004; 172(4):2549-58. DOI: 10.4049/jimmunol.172.4.2549. View

Eichinger K, Kosanovich J, Empey K . Localization of the T-cell response to RSV infection is altered in infant mice. Pediatr Pulmonol. 2017; 53(2):145-153. PMC: 5775046. DOI: 10.1002/ppul.23911. View

Perkins T, Oczypok E, Dutz R, Donnell M, Myerburg M, Oury T . The receptor for advanced glycation end products is a critical mediator of type 2 cytokine signaling in the lungs. J Allergy Clin Immunol. 2019; 144(3):796-808.e12. DOI: 10.1016/j.jaci.2019.03.019. View

Sastry M, Zhang B, Chen M, Joyce M, Kong W, Chuang G . Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus. PLoS One. 2017; 12(10):e0186854. PMC: 5658087. DOI: 10.1371/journal.pone.0186854. View

Hall C, Walsh E, Long C, Schnabel K . Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis. 1991; 163(4):693-8. DOI: 10.1093/infdis/163.4.693. View

10.

Glezen W, Taber L, Frank A, KASEL J . Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986; 140(6):543-6. DOI: 10.1001/archpedi.1986.02140200053026. View

11.

Legg J, Hussain I, Warner J, Johnston S, Warner J . Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med. 2003; 168(6):633-9. DOI: 10.1164/rccm.200210-1148OC. View

12.

Green C, Sande C, de Lara C, Thompson A, Silva-Reyes L, Napolitano F . Humoral and cellular immunity to RSV in infants, children and adults. Vaccine. 2018; 36(41):6183-6190. DOI: 10.1016/j.vaccine.2018.08.056. View

13.

Empey K, Orend J, Peebles Jr R, Egana L, Norris K, Oury T . Stimulation of immature lung macrophages with intranasal interferon gamma in a novel neonatal mouse model of respiratory syncytial virus infection. PLoS One. 2012; 7(7):e40499. PMC: 3391240. DOI: 10.1371/journal.pone.0040499. View

14.

Bont L, Versteegh J, Swelsen W, Heijnen C, Kavelaars A, Brus F . Natural reinfection with respiratory syncytial virus does not boost virus-specific T-cell immunity. Pediatr Res. 2002; 52(3):363-7. DOI: 10.1203/00006450-200209000-00009. View

15.

McLellan J, Chen M, Joyce M, Sastry M, Stewart-Jones G, Yang Y . Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013; 342(6158):592-8. PMC: 4461862. DOI: 10.1126/science.1243283. View

16.

Eichinger K, Egana L, Orend J, Resetar E, Anderson K, Patel R . Alveolar macrophages support interferon gamma-mediated viral clearance in RSV-infected neonatal mice. Respir Res. 2015; 16:122. PMC: 4594958. DOI: 10.1186/s12931-015-0282-7. View

17.

Cerwenka A, Morgan T, Harmsen A, Dutton R . Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection. J Exp Med. 1999; 189(2):423-34. PMC: 2192982. DOI: 10.1084/jem.189.2.423. View